COMMENTARY

Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics

July 26, 2017
By Takashi Ebisawa A third-party probe into a scandal surrounding Xarelto (rivaroxaban) patient surveys wrapped up earlier this month, laying bare a series of problems inside Osaka-based Bayer Yakuhin, the Japan pharma unit Bayer AG. For one, there was a…

To read the full story

COMMENTARY

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

By Tatsuya Otsuka

Driven by changes surrounding the Japanese generic drug market, generic companies are trying to shift from a “generic” to a “specialty” model for their main business, with more and more players steering their focus towards specialized areas to secure profits.The…

By Yoshinori Sagehashi

It’s official. Japan has decided to move ahead with the introduction of a cost-effectiveness assessment (CEA) scheme in April. But people from all walks of life – industry, government officials and academics included - are wondering, “What about the cost…